3 cancer drugs raise risk of fatal side effects

Treatment with three relatively new “targeted” cancer drugs has been linked to a slightly elevated chance of fatal side effects, according to a new analysis led by scientists at Dana-Farber.

The study looked at three drugs: sorafenib (Nexavar), sunitinib (Sutent), and pazopanib (Votrient). Sorafenib is approved to treat kidney and liver cancer, sunitinib to treat kidney cancer and gastrointestinal stromal tumor (GIST), and pazopanib to treat kidney cancer.

Dr. Toni Choueiri, the lead author of the study, says that patients should be aware of the risks and speak with their doctor.